Novo Nordisk acquires Korean approval of ‘Saxenda,’ GLP-1 analogue obesity treatment
Novo Nordisk Korea(President Rana Azfar Zafar) announced that Saxenda(generic name: liraglutide), its new obesity therapy, was approved from the Ministry of Food and Drug Safety on the 21st.
Saxenda is the world’s obesity therapy approved as GLP-1(Glucagon-Like Peptide 1) analogue.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.